OR WAIT null SECS
© 2021 MJH Life Sciences and Modern Retina. All rights reserved.
© 2021 MJH Life Sciences™ and Modern Retina. All rights reserved.
March 07, 2019
Improvement in visual acuity, central retinal thickness, vitreous haze reported at 6 months
March 06, 2019
Intravitreal triamcinolone acetonide, dexamethasone implant superior for regional treatment of disorder
March 01, 2019
January 11, 2019
November 26, 2018
Novel local corticosteroid therapy shows positive efficacy signals, favorable safety profile says Rahul Khurana, MD.
May 01, 2018
Uveitis does not have to be vexing. Here are some basic principles to make it easier for ophthalmologists to identify the disorder, says James Philip Dunn Jr., MD
July 01, 2017
Intravitreal sirolimus 400 mcg (Ospiria, Santen) demonstrated positive results in pivotal trials investigating it as a treatment for non-infectious uveitis of the posterior segment. A New Drug Application is under FDA review.
June 12, 2017
Local therapy plays a significant role in the treatment of uveitis, either as monotherapy or in combination therapy. Alongside a number of pharmacotherapeutic agents, new products and technologies are in development that could expand clinicians’ options and improve outcomes.
April 15, 2017
Results from the Study Assessing double-masKed Uveitis tREAtrement (SAKURA) program support the efficacy and safety of intravitreal sirolimus 440 mcg (Opsiria, Santen) for treating noninfectious uveitis of the posterior segment, said Pauline T. Merrill, MD.